Table 1. Selected trials with a design... | American Society of Hematology

Table 1.

Selected trials with a design that may prevent resistance or intolerance to targeted therapies in CLL

ClinicalTrials.gov ID	Trial name	Treatment	Target	Strategy	Study phase	Reference
NCT02801578		Ibrutinib	BTK	Drug dosing	2/3	Chen et al, Blood, 2018⁴⁵
	Ibrutinib on-off	Ibrutinib	BTK	Temporal sequencing	1
NCT02049515		Duvelisib	PI3K	Temporal sequencing	3
NCT03961672		Duvelisib	PI3K	Temporal sequencing	2
NCT03226301	HO141/VISION	Ibrutinib + venetoclax	BTK, BCL-2	Fixed duration, combination, temporal sequencing	2
NCT02242942	CLL14	Venetoclax + obinutuzumab	BCL-2, CD20	Fixed duration, combination	3	Fischer et al, N Engl J Med., 2019⁵⁷
NCT02756897		Ibrutinib + venetoclax	BTK, BCL-2	Fixed duration, combination	2	Jain et al, N Engl J Med., 2019⁵⁹
	CLARITY	Ibrutinib + venetoclax	BTK, BCL-2	Fixed duration, combination		Hillmen et al, J Clin Oncol., 2019⁶⁰
NCT03534323		Duvelisib + venetoclax	PI3K, BCL-2	Combination	1/2
NCT02268851		Umbralisib + ibrutinib	PI3K, BCL-2	Combination	1/1b
NCT04016805		Ibrutinib, venetoclax, ublituximab + umbralisib	BTK, BCL-2, CD20, PI3K	Combination	2
NCT02639910	COSMOS	Tafasitamab with idelalisib or venetoclax	CD19, PI3K, BCL-2	Combination	2
NCT03379051		Venetoclax, umbralisib + ublituximab	BCL-2, PI3K, CD20	Combination	1/2

ClinicalTrials.gov ID	Trial name	Treatment	Target	Strategy	Study phase	Reference
NCT02801578		Ibrutinib	BTK	Drug dosing	2/3	Chen et al, Blood, 2018⁴⁵
	Ibrutinib on-off	Ibrutinib	BTK	Temporal sequencing	1
NCT02049515		Duvelisib	PI3K	Temporal sequencing	3
NCT03961672		Duvelisib	PI3K	Temporal sequencing	2
NCT03226301	HO141/VISION	Ibrutinib + venetoclax	BTK, BCL-2	Fixed duration, combination, temporal sequencing	2
NCT02242942	CLL14	Venetoclax + obinutuzumab	BCL-2, CD20	Fixed duration, combination	3	Fischer et al, N Engl J Med., 2019⁵⁷
NCT02756897		Ibrutinib + venetoclax	BTK, BCL-2	Fixed duration, combination	2	Jain et al, N Engl J Med., 2019⁵⁹
	CLARITY	Ibrutinib + venetoclax	BTK, BCL-2	Fixed duration, combination		Hillmen et al, J Clin Oncol., 2019⁶⁰
NCT03534323		Duvelisib + venetoclax	PI3K, BCL-2	Combination	1/2
NCT02268851		Umbralisib + ibrutinib	PI3K, BCL-2	Combination	1/1b
NCT04016805		Ibrutinib, venetoclax, ublituximab + umbralisib	BTK, BCL-2, CD20, PI3K	Combination	2
NCT02639910	COSMOS	Tafasitamab with idelalisib or venetoclax	CD19, PI3K, BCL-2	Combination	2
NCT03379051		Venetoclax, umbralisib + ublituximab	BCL-2, PI3K, CD20	Combination	1/2

BCL-2, B-cell lymphoma-2; BTK, Bruton tyrosine kinase; PI3K, phosphatidylinositol 3-kinase.